KEYTRUDA + LENVIMA
A combination of pembrolizumab (Merck) and lenvatinib (Eisai) used in select biomarker-defined endometrial and renal cancers.
Where this therapy is approved with a companion diagnostic
Each row represents a defined combination of indication, biomarker criteria, and KEYTRUDA + LENVIMA. Select a testing pathway to see the eligible companion diagnostic tests.
Approvals where KEYTRUDA + LENVIMA is tied to a specific indication and biomarker definition.
| Indication | Biomarker criteria | Notes | |
|---|---|---|---|
Endometrial Carcinoma (EC) Solid Tumor · Endometrium | Not MSI-High
| View testing pathway → | |
Endometrial Carcinoma (EC) Solid Tumor · Endometrium | proficient mismatch repair (pMMR) proteins
| View testing pathway → |
Approvals defined at the solid tumor level where biomarker criteria determine eligibility for KEYTRUDA + LENVIMA.
No tumor-agnostic companion diagnostic approvals are currently mapped for this therapy.
Tests used in these approvals
These assays are identified in FDA labeling or sponsor materials as companion diagnostics or acceptable tests when considering KEYTRUDA + LENVIMA for eligible patients.